Azathioprine versus Beta Interferons for Relapsing-Remitting Multiple Sclerosis: A Multicentre Randomized Non-Inferiority Trial
Open Access
- 17 November 2014
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 9 (11) , e113371
Abstract
For almost three decades in many countries azathioprine has been used to treat relapsing-remitting multiple sclerosis. However its efficacy was usually considered marginal and following approval of β interferons for this indication it was no longer recommended as first line treatment, even if presently no conclusive direct β interferon-azathioprine comparison exists. To compare azathioprine efficacy versus the currently available β interferons in relapsing-remitting multiple sclerosis, a multicenter, randomized, controlled, single-blinded, non-inferiority trial was conducted in 30 Italian multiple sclerosis centers. Eligible patients (relapsing-remitting course; ≥2 relapses in the last 2 years) were randomly assigned to azathioprine or β interferons. The primary outcome was annualized relapse rate ratio (RR) over 2 years. Key secondary outcome was number of new brain MRI lesions. Patients (n = 150) were randomized in 2 groups (77 azathioprine, 73 β interferons). At 2 years, clinical evaluation was completed in 127 patients (62 azathioprine, 65 β interferons). Annualized relapse rate was 0.26 (95% Confidence Interval, CI, 0.19–0.37) in the azathioprine and 0.39 (95% CI 0.30–0.51) in the interferon group. Non-inferiority analysis showed that azathioprine was at least as effective as β interferons (relapse RRAZA/IFN 0.67, one-sided 95% CI 0.96; p<0.01). MRI outcomes were analyzed in 97 patients (50 azathioprine and 47 β interferons). Annualized new T2 lesion rate was 0.76 (95% CI 0.61–0.95) in the azathioprine and 0.69 (95% CI 0.54–0.88) in the interferon group. Treatment discontinuations due to adverse events were higher (20.3% vs. 7.8%, p = 0.03) in the azathioprine than in the interferon group, and concentrated within the first months of treatment, whereas in the interferon group discontinuations occurred mainly during the second year. The results of this study indicate that efficacy of azathioprine is not inferior to that of β interferons for patients with relapsing-remitting multiple sclerosis. Considering also the convenience of the oral administration, and the low cost for health service providers, azathioprine may represent an alternative to interferon treatment, while the different side effect profiles of both medications have to be taken into account. EudraCT 2006-004937-13Keywords
This publication has 33 references indexed in Scilit:
- Immunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysisCochrane Database of Systematic Reviews, 2013
- Reporting of Noninferiority and Equivalence Randomized TrialsJAMA, 2012
- Azathioprine for multiple sclerosisCochrane Database of Systematic Reviews, 2007
- Reporting of Noninferiority and Equivalence Randomized TrialsJAMA, 2006
- Azathioprine and interferon beta-1b treatment in relapsing-remitting multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2001
- New treatments and azathioprine in multiple sclerosisThe Lancet, 1997
- Lesion Load Quantification in Serial MR of Early Relapsing Multiple Sclerosis Patients in Azathioprine TreatmentEuropean Neurology, 1997
- Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosisAnnals of Neurology, 1996
- Overview of azathioprine treatment in multiple sclerosisThe Lancet, 1991
- Rating neurologic impairment in multiple sclerosisNeurology, 1983